Atlas Trials

Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

Clinical trial NCT07035392 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07035392
Sponsor
Zhangzhou Municipal Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Adebrelimab (SHR-1316)NSCLCChemotherapy
Start date
2025-06-20
Primary completion
2026-12-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.